Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INEC study: Irradiation and Nivolumab in Esophageal Cancer
2023-510124-77-01Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in esophageal cancer and esophagogastric junction cancer (3 cohorts), sponsored by Oslo University Hospital. Primary endpoints: Safety (primary) and Feasibility (primary). Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2023-510124-77-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510124-77-01.